Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 1047 results for drug therapy

  1. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  2. Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

    Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.

  3. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  4. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  5. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (HTG734)

    Evidence-based recommendations on MRI-guided focused ultrasound subthalamotomy for treating Parkinson’s. This involves using ultrasound to destroy tissue in an area of the brain linked to Parkinson’s symptoms.

  6. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's (HTG733)

    Evidence-based recommendations on MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson’s. This involves using ultrasound to destroy tissue in the thalamus.

  7. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

  8. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.

  9. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  10. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

  11. Bimekizumab for treating moderate to severe plaque psoriasis (TA723)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.

  12. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  13. Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

    This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.

  14. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

  15. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

    Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.